Physician profile
Michael Hernandez
NPI 1972501096
$25,568.13
in general payments reported to CMS, 2019-2025
33 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $1,509 · 2021: $1,512 · 2022: $17K · 2023: $1,165 · 2024: $1,393 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.25 |
| Education | $314.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20,008.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,075.98 | 2021-2025 | Evenity, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $933.95 | 2019-2022 | |
| Lilly USA, LLC | $651.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $641.38 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.04 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $241.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $230.17 | 2022-2024 | Arexvy, Shingrix, Bexsero |
| Abbott Laboratories | $177.59 | 2019-2020 | |
| Pfizer INC. | $157.74 | 2022-2025 | |
| Allergan, INC. | $135.10 | 2019-2022 | |
| Genentech, INC. | $125.00 | 2020 | |
| Medtronic, INC. | $123.20 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $106.11 | 2023 | Quviviq |
| Abbvie INC. | $87.12 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $68.10 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $55.02 | 2025 | Zilretta |
| Orthofix Medical, INC. | $52.80 | 2023-2024 | Physio-Stim |
| Sanofi-Aventis U.S. LLC | $48.19 | 2019 | |
| Medtronic USA, INC. | $43.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.62 | 2019-2022 | |
| Ebi, LLC | $31.82 | 2025 | Biomet Ebi Bone Healing System, Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Currax Pharmaceuticals LLC | $28.33 | 2024 | Contrave, Onzetra Xsail |
| Becton, Dickinson and Company | $22.85 | 2022 | |
| Fidia Pharma USA INC. | $22.26 | 2024 | Hyalgan, Triluron, Hymovis |
| Esperion Therapeutics, INC. | $21.48 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.14 | 2025 | |
| Verona Pharma, INC. | $16.65 | 2025 | Ohtuvayre |
| Ethicon US, LLC | $15.31 | 2019 | |
| Dexcom, INC. | $13.67 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $12.82 | 2020 | |
| Edwards Lifesciences Corporation | $11.60 | 2022 | |
| Janssen Biotech, INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.